×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition
STAT
MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis, STAT has learned.
3 days ago
Morphosys says takeover by Novartis on course after report of drug safety concern
Reuters
Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug...
2 days ago
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
BioSpace
Citing anonymous sources involved in a Phase III trial, STAT News reported Sunday that MorphoSys' pelabresib may worsen the risk of...
2 days ago
MorphoSys AG Navigates Takeover and Asset Sale - TipRanks.com
Tipranks
Morphosys (MOR) has released an update. MorphoSys AG has reported a first-quarter revenue of €27.5 million, mainly from royalties, with R&D expenses...
1 day ago
MorphoSys AG Reports First Quarter 2024 Financial Results
Business Wire
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024. “The proposed acquisition by Novartis is advancing...
2 days ago
MorphoSys Stock: Hold Rating Until The Novartis Deal Closes (NASDAQ:MOR)
Seeking Alpha
Novartis acquires MorphoSys for EUR 2.7 billion, a significant premium over the share price, with promising myelofibrosis treatment...
22 hours ago
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, P
Benzinga
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute...
2 days ago
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Fierce Biotech
Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Therapeutics for $750 million.
1 week ago
Pharmalittle: We're reading about MorphoSys drug risks, an AstraZeneca admission, and more
STAT
Orphan drugs for rare diseases may be losing their allure, as sales growth is starting to level off, a new analysis finds.
2 days ago
Novartis will see modest boost to blood cancer portfolio with MorphoSys acquisition
Clinical Trials Arena
On 4 February 2024, Novartis announced its acquisition of the prominent biopharmaceutical company MorphoSys AG. This deal provides Novartis with...
2 months ago